GlassScriptPhysician profile
Parag N Patel
NPI 1598976235
$4,268.35
in general payments reported to CMS, 2019-2025
33 companies · $472 in 2025
The $472 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $730 · 2021: $729 · 2022: $702 · 2023: $416 · 2024: $722 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.83 |
| Education | $153.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $920.30 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $569.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $539.85 | 2019-2025 | Tezspire, Fasenra |
| Sanofi-Aventis U.S. LLC | $252.93 | 2022-2025 | |
| Pfizer INC. | $225.70 | 2019-2022 | |
| Kaleo, INC. | $211.68 | 2019-2024 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $166.64 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.40 | 2023-2024 | Caplyta |
| Optinose US, INC. | $130.56 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.83 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $109.70 | 2019-2025 | |
| Genentech USA, INC. | $107.03 | 2019-2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.75 | 2020-2021 | |
| Ardelyx, INC. | $76.38 | 2024-2025 | Ibsrela |
| Csl Behring | $70.03 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $67.96 | 2023-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $56.88 | 2019-2023 | |
| Abbott Laboratories | $40.94 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Alk-Abello, INC | $39.22 | 2019 | |
| Phadia US INC. | $36.91 | 2020-2023 | Immunocap |
| Shire North American Group INC | $36.63 | 2019 | |
| Grifols USA, LLC | $36.18 | 2020-2023 | Xembify |
| Aimmune Therapeutics, INC. | $30.40 | 2021 | |
| Inspire Medical Systems, INC. | $24.77 | 2023 | Inspire |
| Ars Pharmaceuticals Operations, INC. | $24.48 | 2025 | Neffy |
| Cvrx, INC. | $22.93 | 2024 | Barostim Neo System |
| Stryker Corporation | $22.58 | 2024 | Scopis Ent, Audion Et Dilation System |
| Lundbeck LLC | $18.85 | 2025 | Rexulti |
| Incyte Corporation | $18.24 | 2022 | |
| Bausch Health US, LLC | $16.57 | 2022 | |
| Medtronic, INC. | $16.45 | 2021 | |
| Amgen INC. | $13.62 | 2024 | Tezspire |
| Mylan Specialty L.P. | $12.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parag Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.